Results 211 to 220 of about 12,711,395 (233)

Inhibition of bovine factor IXa and factor Xa.beta. by antithrombin III

Biochemistry, 1976
Factor IXa and factor Xabeta are serine proteases which participate in the middle phase of blood coagulation. These two enzymes are inhibited by antithrombin III by the formation of an enzyme-inhibitor complex containing 1 mol of enzyme and 1 mol of antithrombin III.
K, Kurachi, K, Fujikawa, G, Schmer, E W, Davie   +3 more
openaire   +2 more sources

Kinetics of coagulation factor-X activation by platelet-bound factor IXa

Biochemistry, 1990
Thrombin-activated human platelets, in the presence of factors VIIIa and X, have specific, high-affinity (Kd approximately 0.5 nM), saturable binding sites for factor IXa that are involved in factor X activation [Ahmad, S.S., Rawala-Sheikh, R., & Walsh, P.N. (1989) J. Biol. Chem. 264, 3244-3251].
R, Rawala-Sheikh, S S, Ahmad, B, Ashby, P N, Walsh   +3 more
openaire   +2 more sources

The Regulation of Factor IXa by Phosphatidylserine.

Blood, 2004
Abstract A number of clinical studies have demonstrated correlation between elevated levels of factor IX and the risk of coronary heart disease. Studies by different groups have shown that blocking procoagulant activity of factor IXa could reduce the risk of thrombosis.
Rinku Majumder, Dougald M. Monroe, Daud Cole, Barry R. Lentz   +3 more
openaire   +1 more source

Amphipathic Helices Support Function of Blood Coagulation Factor IXa

Biochemistry, 2000
Blood coagulation factor IXa gains proteolytic efficiency upon binding to a phospholipid membrane. We have found that an amphipathic, membrane-binding peptide from the C2 domain of factor VIII, fVIII(2303)(-23), enhances proteolytic efficiency of factor IXa in the absence of phospholipid membranes. This enhancement is the result of a reduction in the K(
M D, Blostein, A C, Rigby, B C, Furie, B, Furie, G E, Gilbert   +4 more
openaire   +2 more sources

RNA aptamers as reversible antagonists of coagulation factor IXa

Nature, 2002
Many therapeutic agents are associated with adverse effects in patients. Anticoagulants can engender acute complications such as significant bleeding that increases patient morbidity and mortality. Antidote control provides the safest means to regulate drug action.
Christopher P, Rusconi, Elizabeth, Scardino, Juliana, Layzer, George A, Pitoc, Thomas L, Ortel, Dougald, Monroe, Bruce A, Sullenger   +6 more
openaire   +2 more sources

The Second Epidermal Growth Factor-like Domain of Human Factor IXa Mediates Factor IXa Binding to Platelets and Assembly of the Factor X Activating Complex

Biochemistry, 1999
Factor IXa binding to the activated platelet surface is required for efficient catalysis of factor X activation. Platelets possess a specific binding site for factor IXa, occupancy of which has been correlated with rates of factor X activation. However, the specific regions of the factor IXa molecule that are critical to this interaction have not yet ...
M Y, Wong, J A, Gurr, P N, Walsh
openaire   +2 more sources

Coagulation Factor IXa

2013
Paul E. Monahan, William H. Velander, S. Paul Bajaj   +2 more
openaire   +1 more source

Factor IXa Inhibitors

2009
Richard C. Becker, Mark Chan, Emily L. Howard, Kristian C. D. Becker, Christopher P. Rusconi   +4 more
openaire   +1 more source

Intermediate molecular weight-fucosylated chondroitin sulfate from sea cucumber Cucumaria frondosa is a promising anticoagulant targeting intrinsic factor IXa.

International Journal of Biological Macromolecules
Yuanjie Liu, Rongfeng Li, Lin Song, Kecheng Li, Huahua Yu, R. Xing, Song Liu, Pengcheng Li   +7 more
semanticscholar   +1 more source

Binding of coagulation factor IXa to procoagulant platelets revisited: Low affinity and interactions with other factors.

Biochemical and Biophysical Research Communications - BBRC
P. A. Soloveva, N. Podoplelova, M. A. Panteleev   +2 more
semanticscholar   +1 more source